|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61K 38/01 | (2006.01) |
| A61K 38/03 | (2006.01) | ||
| A61K 38/04 | (2006.01) | ||
| A61P 9/00 | (2006.01) | ||
| A61P 11/00 | (2006.01) | ||
| A61P 17/00 | (2006.01) | ||
| A61P 25/00 | (2006.01) | ||
| A61P 31/12 | (2006.01) | ||
| A61P 37/00 | (2006.01) |
| (11) | Number of the document | 2650008 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13002793.1 |
| Date of filing the European patent application | 2009-06-02 | |
| (97) | Date of publication of the European application | 2013-10-16 |
| (45) | Date of publication and mention of the grant of the patent | 2014-12-17 |
| (46) | Date of publication of the claims translation | 2015-03-25 |
| (30) | Number | Date | Country code |
| PCT/EP2008/0043 | 2008-05-30 | WO |
| (72) |
Bonny, Christophe, CH
|
| (73) |
Xigen Inflammation Ltd.,
Arch. Makariou III 195 Neocleous House, 3030 Limassol,
CY
|
| (74) |
Marija LENKUTIENĖ,
Patentinių paslaugų centras, UAB, Jono Basanavičiaus g. 11/1, LT-03108 Vilnius,
LT
|
| (54) | Į ląsteles patenkančių JNK signalo perdavimo kelio peptidinių inhibitorių panaudojimas įvairių vėžinių ligų gydymui |
| Use of cell permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various cancer diseases |
| Payment date | Validity (years) | Amount | |
| 2016-05-25 | 8 | 185.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2017-06-02 |